Genecast (Beijing) and US-based Interpace Form Diagnostics Partnership
publication date: Sep 17, 2019
Genecast (Beijing) Biotech, a cancer diagnostics company, partnered with Interpace Diagnostics of New Jersey to offer translational studies and clinical trial diagnostics to biopharma companies. According to the agreement, Interpace will offer the diagnostic products/services worldwide except in China, where Genecast will be responsible for them. Founded in 2014, Genecast has developed circulating tumor DNA (ctDNA) detection technology that provides individualized cancer diagnoses. In 2017, the company raised $18 million in a Series B round led by Tshinghua Holdings. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.